Cytotoxic Anticancer Agents and Renal Impairment Study: The Challenge Remains
- 1 February 2006
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 24 (4) , 533-536
- https://doi.org/10.1200/jco.2005.03.8299
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Phase I and Pharmacokinetic Study of Pemetrexed Administered Every 3 Weeks to Advanced Cancer Patients With Normal and Impaired Renal FunctionJournal of Clinical Oncology, 2006
- FDA Drug Approval Summary: Pemetrexed for Injection (Alimta®) for the Treatment of Non-Small Cell Lung CancerThe Oncologist, 2005
- Pemetrexed in Malignant Pleural MesotheliomaClinical Cancer Research, 2005
- An evidence-based evaluation of important aspects of empirical antibiotic therapy in febrile neutropenic patientsClinical Microbiology & Infection, 2005
- Intensive Chemotherapy in Patients with LymphomaPublished by S. Karger AG ,2004
- Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural MesotheliomaJournal of Clinical Oncology, 2003
- Phase II Study of Pemetrexed With and Without Folic Acid and Vitamin B12 as Front-Line Therapy in Malignant Pleural MesotheliomaJournal of Clinical Oncology, 2003
- Carboplatin dosing formulae: gender bias and the use of creatinine-based methodologiesEuropean Journal Of Cancer, 2002
- Effect of hydration on methotrexate plasma concentrations in children with acute lymphocytic leukemia.Journal of Clinical Oncology, 1988